DJIA 17,086.63 0.00 0.00%
NASDAQ 4,473.70 0.00 0.00%
S&P 500 1,987.01 0.00 0.00%
market minute promo

PHARMACYCLICS, INC. (NASDAQ: PCYC)

103.92 0.00 (0.00%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PCYC $103.92 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $97.38
Previous Close $103.92
Daily Range $97.05 - $107.24
52-Week Range $82.51 - $154.89
Market Cap $7.8B
P/E Ratio 52.79
Dividend (Yield) $0.00 (0.0%)
Volume 2,052,253
Average Daily Volume 949,854
Current FY EPS $0.30

Sector

Healthcare

Industry

Drugs

PHARMACYCLICS, INC. (PCYC) Description

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases. Website: http://www.pharmacyclics.com/

News & Commentary Rss Feed

1 Drug Critical to Johnson & Johnson's Future Success

The recent approval of Johnson (JNJ) and Pharmacyclics (PCYC) Imbruvica for two forms of blood cancer may be just the beginning.

Medivation Significantly Undervalued, With Xtandi Weeks Away From Prostate Cancer Label Expansion

4 Top Biotechs Expected to Beat Earnings Expectations

Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatm

Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment

3 Stocks Spiking on Unusual Volume

Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

Fire Up The Immuno-Oncology Powerhouses: John McCamant

Pharmacyclics' Imbruvica Under FDA Priority Review - Analyst Blog

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

PCYC, ALXN And PFE, 3 Drugs Stocks Pushing The Industry Lower

Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog

Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog

See More PCYC News...

PCYC's Top Competitors

PCYC $103.92 (0.00%)
Current stock: PCYC
AMGN $122.01 (0.00%)
Current stock: AMGN
GILD $90.34 (0.00%)
Current stock: GILD
BIIB $337.60 (0.00%)
Current stock: BIIB